The new MHRA accredited unit has been actively running trials in its new surroundings since March 25th with excellent on-going patient feedback.

Our new facility is an early phase specialist unit, it is the fourth unit Richmond Pharmacology has opened and we believe it is our best to date. Richmond Pharmacology completely removed the existing facilities in the building and designed all the floors from scratch creating a better patient experience in the process. The new site has previously been used for conducting early Phase trials for more than 30 years.

It is in an ideal location embedded in the King’s College University and teaching hospital campus."The opening of our new research facility, at what was formerly known as the Guy’s Drug Research Unit, is an exciting addition to our research capability, and will help us to provide the best possible support for our clients in their drive to increase the effectiveness and cost efficiency of developing new drugs and taking them to market."

Richmond Pharmacology CEO, Dr Jorg Taubel.Our integrated, MHRA licensed clinical trials pharmacy is staffed by an experienced and dedicated team, supervised by two expert QPs providing quality and flexible service, GMP advice and regulatory support to our clients.Located in centre of London, within close walking distance to key transport links, museums, historic attractions and all that London has to offer, Richmond believes the location will offer unrivalled access to patent recruitment enabling Richmond to maintain its position as Market Leaders in Combined Adaptive Early Phase Trials.

Latest news

Recruiting breastfeeding mothers into clinical trials through transparent and sensitive conversations

April 30, 2024
Richmond Pharmacology's study on merotocin showed low transfer to breast milk, overcoming recruitment challenges through proximity to a maternity ward.
Read more

Announcement of Jorg Becoming President Elect

April 22, 2024
Richmond Pharmacology announces CEO Dr. Jorg Taubel's appointment as President Elect of Germany's AGAH, where he will enhance early-phase clinical research over a six-year term.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event